EGFR and neoplasm: ,18,20 Several retrospective analysis has shown that primary tumor sidedness (PTS) might play a decisive role in the sensitivity to anti-EGFR mAbs therapy,21, 22, 23 and limited benefit was reported in patients with RAS wild-type right-sided tumor.